RT Journal Article
SR Electronic
T1 Clinical Response Following Adjuvant Temozolomide in a Patient with Primary Cerebral Lymphoma
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 4121
OP 4126
VO 24
IS 6
A1 HERWIG M. STRIK
A1 ANNETTE SPREER
A1 HOLGER NAGEL
A1 SONJA JACOB
A1 WOLFRAM JUNG
A1 BERND KITZE
A1 MATHIAS BÄHR
YR 2004
UL http://ar.iiarjournals.org/content/24/6/4121.abstract
AB A 69-year-old female patient was treated for primary CNS-lymphoma (PCNSL) starting from August 2002. As her general condition allowed no high-dose methotrexate (MTX) therapy, radiotherapy was administered as a first-line treatment. CSF involvement could be managed by intrathecal Ara-C. Her general condition and cognitive status stabilized, but did not improve for 3 months. Therefore, oral chemotherapy with Temozolomide 200mg/m2 was initiated. After two courses, which were tolerated without any problems, the patient's Karnofsky performance index had improved from 40% to 50%, the Mini-Mental Status rose from 16 to 27/30. The CSF-cell count was elevated again to 23 cells/μl without signs of meningeal relapse. Unfortunately, the patient died unexpectedly from suspected pulmonary embolism. We conclude that adjuvant Temozolomide chemotherapy can improve the general condition and cognition in patients with PCNSL even when the general condition is poor. Long-term effects and neurotoxicity remain to be analysed in prospective trials, as well as the efficacy in leptomeningeal disease. Copyright© 2004 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved